A Study Comparing the Dulaglutide Pen and the Semaglutide Pen
NCT ID: NCT03724981
Last Updated: 2020-04-24
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
312 participants
INTERVENTIONAL
2018-10-18
2019-04-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools
NCT03598621
A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens
NCT04238962
Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc
NCT04189848
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895
A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens
NCT04152915
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dulaglutide Pen
Injection of commercial dulaglutide pen on a practice pad.
Dulaglutide Pen
Injected on a practice pad.
Semaglutide Pen
Injection of commercial semaglutide pen on a practice pad.
Semaglutide Pen
Injected on a practice pad.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dulaglutide Pen
Injected on a practice pad.
Semaglutide Pen
Injected on a practice pad.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Self-injection naïve to all injectable treatment (for example, diabetes therapies and other medical conditions)
* Injection naïve to performing all injectable treatment (for example, diabetes therapies and other medical conditions) to others
Exclusion Criteria
* Cognitive or physical difficulties that could interfere with ability to understand the training, perform the injection tasks, or complete the study questionnaires as judged by the investigator
* Is a health care practitioner who is trained in giving injections
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Valley Research
Fresno, California, United States
Long Beach Center for Clinical Research
Long Beach, California, United States
Palm Harbor Medical Associates
Palm Harbor, Florida, United States
Georgia Clinical Research
Snellville, Georgia, United States
Cedar-Crosse Research Center
Chicago, Illinois, United States
L-Marc Research Center
Louisville, Kentucky, United States
Evidera
Bethesda, Maryland, United States
Carolina Research Center, Inc.
Shelby, North Carolina, United States
Lillestol Research LLC
Fargo, North Dakota, United States
BRCR Medical Center, Inc.
Camp Hill, Pennsylvania, United States
Juno Research
Houston, Texas, United States
Juno Research, LLC
Houston, Texas, United States
PI-Coor Clinical Research, LLC
Annandale, Virginia, United States
Manassas Clinical Research Center
Manassas, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Matza LS, Boye KS, Stewart KD, Coyne KS, Wullenweber PK, Cutts KN, Jordan JB, Wang Q, Yu M, Currie BM, Malley KG, Ishak KJ, Hietpas RT, Garcia-Perez LE. Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER). Diabetes Obes Metab. 2020 Mar;22(3):355-364. doi: 10.1111/dom.13902. Epub 2019 Dec 19.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H9X-MC-B021
Identifier Type: OTHER
Identifier Source: secondary_id
17155
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.